Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.
Easy and quick administration of biological drugs. All for the convenience of patient care.
Lemborexant by Eisai to help you fall asleep. Chronic sleep loss, go away!
Cheating out of ignorance, or Sleight of hand and no fraud. How pharmaceutical companies scam clinical trials.